Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Registration Number
- NCT05298423
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.
- Detailed Description
As of protocol amendment 4, participants receiving combination vibostolimab and pembrolizumab (MK-7684A) discontinued treatment due to lack of efficacy observed in other MK-7684A studies, and are given the option to transition to durvalumab therapy.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 611
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy pembrolizumab/vibostolimab For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles. As of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy. pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy durvalumab For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles. As of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy. pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy cisplatin For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles. As of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy. pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy pemetrexed For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles. As of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy. pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy etoposide For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles. As of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy. pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy carboplatin For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles. As of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy. pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy paclitaxel For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles. As of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy. pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy thoracic radiotherapy For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles. As of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy. chemotherapy+radiotherapy+durvalumab durvalumab For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles. chemotherapy+radiotherapy+durvalumab cisplatin For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles. chemotherapy+radiotherapy+durvalumab pemetrexed For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles. chemotherapy+radiotherapy+durvalumab etoposide For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles. chemotherapy+radiotherapy+durvalumab carboplatin For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles. chemotherapy+radiotherapy+durvalumab paclitaxel For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles. chemotherapy+radiotherapy+durvalumab thoracic radiotherapy For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles.
- Primary Outcome Measures
Name Time Method Number of Participants Who Experience at Least One Adverse Event (AE) Up to approximately 48 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE) Up to approximately 48 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (160)
VA Long Beach Healthcare System ( Site 2831)
🇺🇸Long Beach, California, United States
VA West Los Angeles Medical Center ( Site 2808)
🇺🇸Los Angeles, California, United States
Millennium Oncology Research Clinic ( Site 2801)
🇺🇸Hollywood, Florida, United States
Mid Florida Hematology and Oncology Center ( Site 2800)
🇺🇸Orange City, Florida, United States
Moffitt Cancer Center ( Site 2818)
🇺🇸Tampa, Florida, United States
University of Chicago Medical Center ( Site 2828)
🇺🇸Chicago, Illinois, United States
Franciscan St. Francis Health ( Site 2812)
🇺🇸Indianapolis, Indiana, United States
MFSMC-HJWCI ( Site 2804)
🇺🇸Baltimore, Maryland, United States
Boston Medical Center ( Site 2829)
🇺🇸Boston, Massachusetts, United States
University of Massachusetts Chan Medical School ( Site 2815)
🇺🇸Worcester, Massachusetts, United States
University of Missouri Hospital ( Site 2839)
🇺🇸Columbia, Missouri, United States
Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837)
🇺🇸Springfield, Missouri, United States
Rutgers Cancer Institute of New Jersey ( Site 2805)
🇺🇸New Brunswick, New Jersey, United States
Icahn School of Medicine at Mount Sinai ( Site 2821)
🇺🇸New York, New York, United States
White Plains Hospital ( Site 2835)
🇺🇸White Plains, New York, United States
Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 2816)
🇺🇸Portland, Oregon, United States
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 2827)
🇺🇸Lancaster, Pennsylvania, United States
Thomas Jefferson University - Clinical Research Institute ( Site 2813)
🇺🇸Philadelphia, Pennsylvania, United States
Millennium Research & Clinical Development ( Site 2811)
🇺🇸Houston, Texas, United States
Central Texas Veterans health care-Oncology & Hematology ( Site 2819)
🇺🇸Temple, Texas, United States
MultiCare Health System ( Site 2817)
🇺🇸Tacoma, Washington, United States
Instituto Médico Río Cuarto ( Site 3600)
🇦🇷Rio Cuarto, Cordoba, Argentina
Sanatorio Parque ( Site 3602)
🇦🇷Rosario, Santa Fe, Argentina
Clinica Adventista Belgrano ( Site 3601)
🇦🇷Caba, Argentina
Canberra Hospital ( Site 0010)
🇦🇺Canberra, Australian Capital Territory, Australia
Icon Cancer Centre Hobart ( Site 0003)
🇦🇺Hobart, Tasmania, Australia
Ballarat Health Services-Medical Oncology ( Site 0002)
🇦🇺Ballarat Central, Victoria, Australia
Frankston Hospital-Oncology and Haematology ( Site 0009)
🇦🇺Frankston, Victoria, Australia
St Vincent's Hospital-Oncology Clinical Trials ( Site 0005)
🇦🇺Melbourne, Victoria, Australia
Hospital Nossa Senhora da Conceição ( Site 0111)
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0105)
🇧🇷Rio de Janeiro, Brazil
A. C. Camargo Cancer Center-CAPEC ( Site 0102)
🇧🇷Sao Paulo, Brazil
James Lind Centro de Investigacion del Cancer ( Site 0202)
🇨🇱Temuco, Araucania, Chile
Biocenter ( Site 0208)
🇨🇱Concepcion, Biobio, Chile
FALP-UIDO ( Site 0205)
🇨🇱Santiago, Region M. De Santiago, Chile
Centro de Oncología de Precisión ( Site 0209)
🇨🇱Santiago, Region M. De Santiago, Chile
Bradfordhill ( Site 0200)
🇨🇱Santiago, Region M. De Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 0203)
🇨🇱Viña del Mar, Valparaiso, Chile
Beijing Cancer hospital-intrathoratic deparmtment II ( Site 0328)
🇨🇳Beijing, Beijing, China
Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 0309)
🇨🇳Beijing, Beijing, China
Beijing Peking Union Medical College Hospital-pneumology department ( Site 0300)
🇨🇳Beijing, Beijing, China
Army Medical Center of People's Liberation Army-Oncology Department ( Site 0321)
🇨🇳Chongqing, Chongqing, China
Fujian Medical University Union Hospital-1 Bingfanglou ( Site 0330)
🇨🇳Fuzhou Fujian, Fujian, China
Fujian Provincial Cancer Hospital ( Site 0316)
🇨🇳Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University-oncology ( Site 0317)
🇨🇳Xiamen, Fujian, China
Southern Medical University Nanfang Hospital-Department of Oncology ( Site 0336)
🇨🇳Guangzhou, Guangdong, China
Fourth Hospital of Hebei Medical University ( Site 0331)
🇨🇳Shijiazhuang, Hebei, China
Henan Cancer Hospital ( Site 0333)
🇨🇳Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0315)
🇨🇳Wuhan, Hubei, China
Hubei Cancer Hospital ( Site 0311)
🇨🇳Wuhan, Hubei, China
Xiangya Hospital Central South University-Oncology department ( Site 0310)
🇨🇳Changsha, Hunan, China
Hunan Cancer Hospital ( Site 0307)
🇨🇳Changsha, Hunan, China
The Second Affiliated Hospital of Soochow University ( Site 0314)
🇨🇳Suzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University ( Site 0305)
🇨🇳Zhenjiang, Jiangsu, China
Jilin Cancer Hospital-oncology department ( Site 0319)
🇨🇳Changchun, Jilin, China
Shandong Provincial Hospital ( Site 0326)
🇨🇳Jinan, Shandong, China
Qingdao Central Hospital-Endocrinology ( Site 0332)
🇨🇳Qingdao, Shandong, China
Shanghai Chest Hospital-Radiotherapy Department ( Site 0306)
🇨🇳Shanghai, Shanghai, China
Fudan University Shanghai Cancer Center ( Site 0304)
🇨🇳Shanghai, Shanghai, China
Shanghai Pulmonary Hospital-Radiotherapy department ( Site 0335)
🇨🇳Shanghai, Shanghai, China
Shanxi Cancer Hospital-Pulmonology ( Site 0322)
🇨🇳Taiyuan, Shanxi, China
West China Hospital of Sichuan University ( Site 0324)
🇨🇳Cheng Du, Sichuan, China
Tianjin Cancer Hospital ( Site 0329)
🇨🇳Tianjin, Tianjin, China
Hangzhou Cancer Hospital-Medical Oncology ( Site 0302)
🇨🇳Hangzhou, Zhejiang, China
The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301)
🇨🇳Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 0308)
🇨🇳Hangzhou, Zhejiang, China
CIMCA ( Site 0501)
🇨🇷San José, San Jose, Costa Rica
PROCLINICAL Pharma ( Site 0504)
🇨🇷San José, San Jose, Costa Rica
Hospital Metropolitano - Sede Lindora ( Site 0503)
🇨🇷Santa Ana, San Jose, Costa Rica
Masarykuv onkologicky ustav ( Site 3500)
🇨🇿Brno, Brno-mesto, Czechia
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 3502)
🇨🇿Ostrava, Moravskoslezsky Kraj, Czechia
Instituto de Oncologia ( Site 3003)
🇩🇴Santo Domingo, Distrito Nacional, Dominican Republic
Onconet ( Site 3002)
🇩🇴Distrito Nacional, Santo Domingo, Dominican Republic
Klinikum Chemnitz-Klinik für Innere Medizin IV ( Site 0607)
🇩🇪Chemnitz, Sachsen, Germany
LungenClinic Grosshansdorf-Onkologie ( Site 0602)
🇩🇪Grosshansdorf, Schleswig-Holstein, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel-Medizinische Klinik II, Hämatologie und Onkolo
🇩🇪Kiel, Schleswig-Holstein, Germany
Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 0603
🇩🇪Berlin, Germany
Errikos Dunant Hospital Center-Second Department of Oncology and Clinical Trials Unit ( Site 0703)
🇬🇷Athens, Attiki, Greece
Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0706)
🇬🇷Athens, Attiki, Greece
Sotiria Thoracic Diseases Hospital of Athens ( Site 0704)
🇬🇷Athens, Attiki, Greece
Metropolitan Hospital ( Site 0702)
🇬🇷Athens, Attiki, Greece
General Oncology Hospital of Kifissia "Agioi Anargiroi"-2nd Department of Medical Oncology ( Site 07
🇬🇷Nea Kifissia, Attiki, Greece
University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 0700)
🇬🇷Heraklion, Irakleio, Greece
European Interbalkan Medical Center ( Site 0701)
🇬🇷Thessaloniki, Greece
Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 0802)
🇬🇹Ciudad de Guatemala, Guatemala
MEDI-K ( Site 0807)
🇬🇹Guatemala, Guatemala
Centro Regional de Sub Especialidades Médicas SA ( Site 0801)
🇬🇹Quetzaltenango, Guatemala
Centro Medico Integral De Cancerología (CEMIC) ( Site 0805)
🇬🇹Quetzaltenango, Guatemala
Rambam Health Care Campus-Oncology ( Site 1001)
🇮🇱Haifa, Israel
Shaare Zedek Medical Center ( Site 1003)
🇮🇱Jerusalem, Israel
Rabin Medical Center ( Site 1004)
🇮🇱Petah Tikva, Israel
Sheba Medical Center-ONCOLOGY ( Site 1000)
🇮🇱Ramat Gan, Israel
Sourasky Medical Center ( Site 1002)
🇮🇱Tel Aviv, Israel
Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia medica Toraco-Polmonare ( Site 1107)
🇮🇹Napoli, Campania, Italy
Policlinico Universitario Campus Bio-Medico-Radiation Oncology ( Site 1101)
🇮🇹Roma, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1100)
🇮🇹Milan, Lombardia, Italy
Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1102)
🇮🇹Monza, Lombardia, Italy
Fondazione IRCCS Policlinico San Matteo ( Site 1103)
🇮🇹Pavia, Lombardia, Italy
Azienda Ospedaliera Spedali Civili di Brescia ( Site 1105)
🇮🇹Brescia, Italy
Ospedale San Raffaele ( Site 1104)
🇮🇹Milano, Italy
National Hospital Organization Shikoku Cancer Center ( Site 1211)
🇯🇵Matsuyama, Ehime, Japan
Kurume University Hospital ( Site 1212)
🇯🇵Kurume, Fukuoka, Japan
Kobe Minimally Invasive Cancer Center ( Site 1210)
🇯🇵Kobe, Hyogo, Japan
Kanagawa cancer center ( Site 1204)
🇯🇵Yokohama, Kanagawa, Japan
Miyagi Cancer Center ( Site 1200)
🇯🇵Natori, Miyagi, Japan
Sendai Kousei Hospital ( Site 1213)
🇯🇵Sendai, Miyagi, Japan
Niigata Cancer Center Hospital ( Site 1205)
🇯🇵Niigata-shi, Niigata, Japan
Kansai Medical University Hospital ( Site 1207)
🇯🇵Hirakata, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital ( Site 1208)
🇯🇵Takatsuki, Osaka, Japan
Saitama Prefectural Cancer Center ( Site 1201)
🇯🇵Ina-machi, Saitama, Japan
Japanese Foundation for Cancer Research ( Site 1202)
🇯🇵Koto, Tokyo, Japan
Showa University Hospital ( Site 1203)
🇯🇵Shinagawa, Tokyo, Japan
Osaka International Cancer Institute ( Site 1209)
🇯🇵Osaka, Japan
Chungbuk National University Hospital-Internal medicine ( Site 2400)
🇰🇷Cheongju-si, Chungbuk, Korea, Republic of
The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2401)
🇰🇷Suwon-si, Kyonggi-do, Korea, Republic of
Ajou University Hospital-Hematology-Oncology ( Site 2402)
🇰🇷Suwon-si, Kyonggi-do, Korea, Republic of
Severance Hospital, Yonsei University Health System-Lung Cancer Center ( Site 2403)
🇰🇷Seoul, Korea, Republic of
University Malaya Medical Centre-Clinical Oncology ( Site 1402)
🇲🇾Lembah Pantai, Kuala Lumpur, Malaysia
Hospital Pulau Pinang ( Site 1400)
🇲🇾George Town, Pulau Pinang, Malaysia
Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1401)
🇲🇾Kuala Lumpur, Malaysia
Arké SMO S.A. de C.V. ( Site 1504)
🇲🇽Mexico, Distrito Federal, Mexico
Actualidad Basada en la Investigación del Cáncer-Lung Cancer ( Site 1505)
🇲🇽Guadalajara, Jalisco, Mexico
Centro Oncologico de Chihuahua-Unidad de Investigacion Clinica ( Site 1507)
🇲🇽Chihuahua, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 1501)
🇲🇽Oaxaca, Mexico
THE MEDICAL CITY-Cancer Research Center ( Site 3200)
🇵🇭Pasig, National Capital Region, Philippines
Veterans Memorial Medical Center-Section of Oncology ( Site 3201)
🇵🇭Quezon City, National Capital Region, Philippines
Champalimaud Foundation ( Site 2003)
🇵🇹Lisbon, Lisboa, Portugal
Hospital CUF Descobertas ( Site 2006)
🇵🇹Lisbon, Lisboa, Portugal
Unidade Local de Saude de Santo António - Hospital Santo António ( Site 2004)
🇵🇹Porto, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2001)
🇵🇹Porto, Portugal
Centrul Medical Medicover Victoria ( Site 2106)
🇷🇴Bucharest, Bucuresti, Romania
Amethyst Radiotherapy Center ( Site 2102)
🇷🇴Florești, Cluj, Romania
Centrul de Oncologie "Sfântul Nectarie" ( Site 2100)
🇷🇴Craiova, Dolj, Romania
Cabinet Medical Oncomed ( Site 2101)
🇷🇴Timisoara, Timis, Romania
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2610)
🇹🇷Istanbul, Turkey
Radiology Therapeutic Center ( Site 2108)
🇷🇴Otopeni, Ilfov, Romania
Centrul Medical Neolife- Baneasa ( Site 2110)
🇷🇴Bucuresti, Romania
Abraham Oncology ( Site 2303)
🇿🇦Richards Bay, Kwazulu-Natal, South Africa
Cape Town Oncology Trials ( Site 2306)
🇿🇦Cape Town, Western Cape, South Africa
Hospital Universitari Vall d'Hebron ( Site 2501)
🇪🇸Barcelona, Cataluna, Spain
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
🇪🇸Barcelona, Cataluna, Spain
CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2502)
🇪🇸Santiago de Compostela, La Coruna, Spain
Ege University Medicine of Faculty-Chest Diseases Department ( Site 2603)
🇹🇷Bornova, Izmir, Turkey
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2607)
🇹🇷Adana, Turkey
Ankara Gülhane Eitim ve Aratrma Hastanesi-Oncology ( Site 2602)
🇹🇷Ankara, Turkey
Hacettepe Universitesi-oncology hospital ( Site 2605)
🇹🇷Ankara, Turkey
Memorial Ankara Hastanesi-Medical Oncology ( Site 2609)
🇹🇷Ankara, Turkey
Ankara City Hospital-Medical Oncology ( Site 2601)
🇹🇷Ankara, Turkey
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2304)
🇿🇦Port Elizabeth, Eastern Cape, South Africa
The Oncology Centre ( Site 2300)
🇿🇦Durban, Kwazulu-Natal, South Africa
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2504)
🇪🇸Pozuelo de Alarcon, Madrid, Comunidad De, Spain
Medipol Mega Universite Hastanesi-oncology ( Site 2611)
🇹🇷Stanbul, Istanbul, Turkey
Wilgers Oncology Centre ( Site 2301)
🇿🇦Pretoria, Gauteng, South Africa
I.E.U. Medical Point Hastanesi-Oncology ( Site 2612)
🇹🇷Izmir, Turkey
Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 2905)
🇺🇦Kropyvnytskyi, Kirovohradska Oblast, Ukraine
Municipal non-profit enterprise "Lviv Territorial Medical Union "Multidisciplinary Clinical Hospital
🇺🇦Lviv, Lvivska Oblast, Ukraine
Rivne Regional Clinical Hospital ( Site 2919)
🇺🇦Rivne, Rivnenska Oblast, Ukraine
Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council"
🇺🇦Vinnytsia, Vinnytska Oblast, Ukraine
Volyn Regional clinical hospital. Regional Medical Oncology Centre. Oncology chemotherapy department
🇺🇦Lutsk, Volynska Oblast, Ukraine
Universal Clinic Oberig-Oncology Center ( Site 2916)
🇺🇦Kyiv, Ukraine